Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan
— The study’s primary objective is to evaluate the safety of Lomecel-B™ in Japan’s elderly population…
— The study’s primary objective is to evaluate the safety of Lomecel-B™ in Japan’s elderly population…
MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company…
MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company…
Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for…
Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for…
TNF is involved in the development of Alzheimer’s Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™…
TNF is involved in the development of Alzheimer’s Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™…
Broadcasting Live on Wednesday April 19th at 3:45 PM ET TARRYTOWN, NY, April 19, 2023…
Broadcasting Live on Wednesday April 19th at 3:45 PM ET TARRYTOWN, NY, April 19, 2023…
New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the…
New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the…
BASKING RIDGE, NJ, April 19, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
BASKING RIDGE, NJ, April 19, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology…
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology…
MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
– Data shows achievement of primary endpoint of decreasing esophageal intraepithelial eosinophil count and positive…
– Data shows achievement of primary endpoint of decreasing esophageal intraepithelial eosinophil count and positive…
LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”)…